<div id="readability-page-1"><p><span>Quince Therapeutics (NASDAQ:QNCX - Get Free Report)</span> had its price target lifted by equities research analysts at D. Boral Capital  from $4.00 to $5.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. D. Boral Capital's price target suggests a potential upside of 29.70% from the stock's current price.</p><div><p><span></span><span>Get <strong>Quince Therapeutics</strong> alerts:</span></p></div><p>A number of other equities research analysts also recently issued reports on the company. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Quince Therapeutics in a research report on Monday, December 8th. Zacks Research raised shares of Quince Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 26th. One equities research analyst  has rated the stock with a Strong Buy rating, five have issued  a Buy rating, one  has given a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, Quince Therapeutics  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.20.</p><p><b>Read Our Latest Report on Quince Therapeutics</b></p><h2>Quince Therapeutics Price Performance</h2><p>Shares of QNCX stock traded down $0.37 during trading on Monday, reaching $3.86. The company had a trading volume of 955,662 shares, compared to its average volume of 333,276. Quince Therapeutics has a one year low of $0.72 and a one year high of $4.55. The firm's 50 day simple moving average is $2.34 and its two-hundred day simple moving average is $1.84. The company has a market capitalization of $214.65 million, a PE ratio of -3.19 and a beta of 1.02. </p><p>Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05).  Analysts forecast that  Quince Therapeutics will post -1.21 earnings per share for the current year. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its stake in  Quince Therapeutics by 21.6% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company's stock worth $5,010,000 after buying an additional 545,427 shares during the period.  Vanguard Group Inc. lifted its holdings in shares of  Quince Therapeutics by 21.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company's stock worth $2,874,000 after purchasing an additional 309,349 shares in the last quarter.  Millennium Management LLC grew its position in  Quince Therapeutics by 1,152.9% in the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company's stock valued at $2,260,000 after purchasing an additional 1,276,094 shares during the period.  Ieq Capital LLC bought a new stake in  Quince Therapeutics during the 1st quarter valued at $1,073,000.  Finally, ADAR1 Capital Management LLC raised its holdings in  Quince Therapeutics by 442.1% during the third quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company's stock worth $1,263,000 after buying an additional 632,076 shares during the last quarter. 30.75% of the stock is owned by institutional investors. </p><h2>About Quince Therapeutics</h2> (Get Free Report)<p>Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Quince Therapeutics</li><li>What is the MACD Indicator and How to Use it in Your Trading</li><li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li><li>What is the S&amp;P/TSX Index?</li><li>Rivian’s Autonomy Bombshell Changes Everything—Even Its Valuation</li><li>What Investors Need to Know to Beat the Market</li><li>Financial Sector Breaks Out as Capital Rotates and Leadership Shifts</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UU5DWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UU5DWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Quince Therapeutics Right Now?</h2><p>Before you consider Quince Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quince Therapeutics wasn't on the list.</p><p>While Quince Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

QNCX

<p>D. Boral Capital raised Quince Therapeutics' price target from $4.00 to $5.00, maintaining a "buy" rating, suggesting a 29.70% potential upside. Quince has a consensus "Moderate Buy" rating with a $8.20 price target. The stock traded at $3.86, with a market cap of $214.65 million. Institutional investors have increased their stakes, with notable increases by Nantahala Capital and Vanguard Group. Quince focuses on therapeutics for rare diseases, with EryDex as a lead asset for neurodegenerative disorders.</p>

Quince Therapeutics (NASDAQ:QNCX) Price Target Raised to $5.00 at D. Boral Capital